Levin College of Law

Lars Noah


Mailing Address:
Box #117625 Gainesville, FL 32611

(352) 273-0923


Lars Noah is a Professor of Law at the University of Florida, where he has taught courses in Administrative Law, Medical Technology, Public Health Law, and Torts, among other subjects.  Professor Noah has published more than fifty scholarly articles on a wide range of subjects as well as a casebook that focuses on the regulation of pharmaceuticals and medical devices: Law, Medicine, and Medical Technology (Foundation Press 3d ed. 2012).  He has served as a visiting professor at Georgetown, Texas, Vanderbilt, George Washington, U.C. Hastings, and Washington & Lee, and he has worked with expert committees at the National Academy of Sciences and the National Institutes of Health.  Before entering academia in 1994, Professor Noah clerked for Chief Judge Abner J. Mikva on the U.S. Court of Appeals for the D.C. Circuit and then practiced law for three years at Covington & Burling in Washington, D.C.  He received his B.A. and J.D. (both magna cum laude) from Harvard University.


J.D., Harvard University (magna cum laude)
B.A., Harvard University (magna cum laude)

Teaching & Scholarship

Medical Technology, Torts, Public Health Law, Products Liability, Administrative Law, S.T.E.M. subjects

Professional Activities

  • University of Florida: Joined College of Law faculty in 1994; Teacher of the Year (1995, 1998 & 2004)
  • Visiting Faculty: Georgetown University, George Washington University, University of Texas, University of California (Hastings), Vanderbilt University, Washington & Lee University.
  • Consultant: Institute of Medicine (food additives, 1997; dietary supplements, 2001; dioxins, 2003; food safety, 2009); National Institutes of Health (medical device retrieval, 2000); U.S. House Judiciary Committee (FCC merger approvals, 1999); U.S. Senate Judiciary Committee (tobacco legislation, 1997-98); Food and Drug Administration (nonprescription drug labeling, 1995).


Torts - LAW 5700
  • Civil liability for harm caused by wrongful acts that violate non-contractual duties imposed by law. The course covers negligence and other theories of liability as prescribed by the instructor.
Medical Technology And The Law - LAW 6724
  • Course considers the many ways our society manages medical technologies (primarily pharmaceuticals and medical devices), including direct federal regulation of research, development and marketing; products liability doctrines affecting manufacturing, design, and labeling; and the impacts of insurance systems and intellectual property regimes on access and innovation.
Public Health Law - LAW 6XXX
  • Addresses the powers and duties of government to assure the conditions for healthy populations and examines tensions between this goal and civil liberties, such as infectious disease surveillance vs. privacy, vaccine requirements vs. conscientious objection, forced treatment/quarantine vs. autonomous medical decisionmaking, and advertising restrictions vs. free expression.




Selected Articles

  • State Affronts to Federal Primacy in the Licensure of Pharmaceutical Products, 2016 Mich. St. L. Rev. 1 (2016). [SSRN]
  • Growing Organs in the Lab: Tissue Engineers Confront Institutional “Immune” Responses, 55 Jurimetrics J. 297 (2015). [SSRN]
  • Product Hopping 2.0: Getting the FDA to Yank Your Original License Beats Stacking Patents, 19 Marq. Intell. Prop. L. Rev. 161 (2015). [SSRN]
  • Governance by the Backdoor: Administrative Law(lessness?) at the FDA, 93 Neb. L. Rev. 89 (2014). [SSRN]
  • Permission to Speak Freely?, 162 U. Pa. L. Rev. Online 248 (2014). [SSRN]
  • Genetic Modification and Food Irradiation: Are Those Strictly on a Need-to-Know Basis?, 118 Penn. St. L. Rev. 759 (2014). [SSRN]
  • Turn the Beat Around?: Deactivating Implanted Cardiac-Assist Devices, 39 Wm. Mitchell L. Rev. 1229 (2013). [SSRN]
  • Whatever Happened to the “Frankenfish”?: The FDA’s Foot-Dragging on Transgenic Salmon, 65 Me. L. Rev. 606 (2013). [SSRN]
  • Truth or Consequences?: Commercial Free Speech vs. Public Health Promotion (at the FDA), 21 Health Matrix 31 (2011). [SSRN]
  • Coerced Participation in Clinical Trials: Conscripting Human Research Subjects, 62 Admin. L. Rev. 329 (2010). [SSRN]
  • Adding Insult to Injury: Paying for Harms Caused by a Competitor’s Copycat Product, 45 Tort Trial & Ins. Prac. L.J. 673 (2010).
  • Comfortably Numb: Medicalizing (and Mitigating) Pain-and-Suffering Damages, 42 U. Mich. J.L. Reform 431 (2009). [SSRN]
  • This Is Your Products Liability Restatement on Drugs, 74 Brook. L. Rev. 839 (2009). [SSRN]
  • Platitudes About “Product Stewardship” in Torts: Continuing Drug Research and Education, 15 Mich. Tel. & Tech. L. Rev. 359 (2009). [SSRN]
  • The Little Agency That Could (Act with Indifference to Constitutional and Statutory Strictures), 93 Cornell L. Rev. 901 (2008). [SSRN]
  • Too High a Price for Some Drugs?: The FDA Burdens Reproductive Choice, 44 San Diego L. Rev. 231 (2007). [SSRN]
  • Treat Yourself: Is Self-Medication the Prescription for What Ails American Health Care?, 19 Harvard J.L. & Tech. 359 (2006). [SSRN]
  • Managing Biotechnology’s [R]evolution: Has Guarded Enthusiasm Become Benign Neglect?, 11 Va. J.L. & Tech. 4 (2006). [SSRN]
  • An Inventory of Mathematical Blunders in Applying the Loss-of-a-Chance Doctrine, 24 Rev. Litig. 369 (2005). [SSRN]
  • Medical Education and Malpractice: What’s the Connection?, 15 Health Matrix 149 (2005). [SSRN]
  • Ambivalent Commitments to Federalism in Controlling the Practice of Medicine, 53 U. Kan. L. Rev. 149 (2004). [SSRN]
  • A Postmodernist Take on the Human Embryo Research Debate, 36 Conn. L. Rev. 1133 (2004). [SSRN]
  • Deputizing Institutional Review Boards to Police (Audit?) Biomedical Research, 25 J. Legal Med. 267 (2004).
  • Letter, Trends in Assisted Reproductive Technology, 351 New Eng. J. Med. 398 (2004).
  • Assisted Reproductive Technologies and the Pitfalls of Unregulated Biomedical Innovation, 55 Fla. L. Rev. 603 (2003). [SSRN]
  • Challenges in the Federal Regulation of Pain Management Technologies, 31 J.L. Med. & Ethics 55 (2003). [SSRN]
  • Triage in the Nation’s Medicine Cabinet: The Puzzling Scarcity of Vaccines and Other Drugs, 54 S.C. L. Rev. 741 (2003). [SSRN]
  • Letter, Pharmacogenetics, 348 New Eng. J. Med. 2042 (2003).
  • The Coming Pharmacogenomics Revolution: Tailoring Drugs to Fit Patients’ Genetic Profiles, 43 Jurimetrics J. 1 (2002). [SSRN]
  • Informed Consent and the Elusive Dichotomy Between Standard and Experimental Therapy, 28 Am. J.L. & Med. 361 (2002). [SSRN]
  • Medicine’s Epistemology: Mapping the Haphazard Diffusion of Knowledge in the Biomedical Community, 44 Ariz. L. Rev. 373 (2002).
  • Letter, Attorney General’s Intrusion into Clinical Practice, 346 New Eng. J. Med. 1918 (2002).
  • Letter, Standards for Medical Expert Testimony, 288 JAMA 2971 (2002).
  • Civil Jury Nullification, 86 Iowa L. Rev. 1601 (2001).
  • A Miscarriage in the Drug Approval Process?: Mifepristone Embroils the FDA in Abortion Politics, 36 Wake Forest L. Rev. 571 (2001).
  • Rewarding Regulatory Compliance: The Pursuit of Symmetry in Products Liability, 88 Geo. L.J. 2147 (2000).
  • Interpreting Agency Enabling Acts: Misplaced Metaphors in Administrative Law, 41 Wm. & Mary L. Rev. 1463 (2000).
  • Scientific “Republicanism”: Expert Peer Review and the Quest for Regulatory Deliberation, 49 Emory L.J. 1033 (2000).
  • Divining Regulatory Intent: The Place for a “Legislative History” of Agency Rules, 51 Hastings L.J. 255 (2000).
  • What’s Wrong with “Constitutionalizing Food and Drug Law”?, 75 Tul. L. Rev. 137 (2000).
  • Peer Review and Regulatory Reform, 30 Envtl. L. Rep. 10,606 (2000).
  • Pigeonholing Illness: Medical Diagnosis as a Legal Construct, 50 Hastings L.J. 241 (1999).
  • Doubts About Direct Final Rulemaking, 51 Admin. L. Rev. 401 (1999).
  • The Executive Line Item Veto and the Judicial Power to Sever: What’s the Difference?, 56 Wash. & Lee L. Rev. 235 (1999).
  • Starting from Scratch?: Reinventing the Food Additive Approval Process, 78 B.U. L. Rev. 329 (1998).
  • Sanctifying Scientific Peer Review: Publication as a Proxy for Regulatory Decisionmaking, 59 U. Pitt. L. Rev. 677 (1998).
  • Authors, Publishers, and Products Liability: Remedies for Defective Information in Books, 77 Or. L. Rev. 1195 (1998). [SSRN]
  • Regulating Cigarettes: (Non)sense and Sensibility, 22 S. Ill. U. L.J. 677 (1998).
  • Administrative Arm-Twisting in the Shadow of Congressional Delegations of Authority, 1997 Wis. L. Rev. 873 (1997).
  • Advertising Prescription Drugs to Consumers: Assessing the Regulatory and Liability Issues, 32 Ga. L. Rev. 141 (1997).
  • The FDA’s New Policy on Guidelines: Having Your Cake and Eating It Too, 47 Cath. U. L. Rev. 113 (1997).
  • NAFTA’s Impact on the Trade in Pharmaceuticals, 33 Hous. L. Rev. 1293 (1997).
  • Reconceptualizing Federal Preemption of Tort Claims as the Government Standards Defense, 37 Wm. & Mary L. Rev. 903 (1996).
  • Nicotine Withdrawal: Assessing the FDA’s Effort to Regulate Tobacco Products, 48 Ala. L. Rev. 1 (1996).
  • Sham Petitioning as a Threat to the Integrity of the Regulatory Process, 74 N.C. L. Rev. 1 (1995).
  • The Imperative to Warn: Disentangling the “Right to Know” from the “Need to Know” About Consumer Product Hazards, 11 Yale J. on Reg. 293 (1994).
  • Constraints on the Off-Label Uses of Prescription Drug Products, 16 J. Prods. & Toxics Liab. 139 (1994).
  • Amplification of Federal Preemption in Medical Device Cases, 49 Food & Drug L.J. 183 (1994).
  • Death of a Salesman: To What Extent Can the FDA Regulate Promotional Statements?, 47 Food & Drug L.J. 309 (1992).
  • Note, The Politics of En Banc Review, 102 Harv. L. Rev. 864 (1989).